Amoxicillin Tabs for Oral Suspension Rx
Generic Name and Formulations:
Amoxicillin (as trihydrate) 200mg, 400mg, 600mg; tabs for oral susp; strawberry-flavor; contains phenylalanine.
Various generic manufacturers
Indications for Amoxicillin Tabs for Oral Suspension:
Susceptible infections including ear/nose/throat (ENT), lower respiratory tract, skin and skin structure, genitourinary tract, acute uncomplicated gonorrhea.
Use other forms.
Do not chew or swallow tablets; mix with 2 teaspoonsful of water and drink entire mixture immediately. Do not subdivide doses (use 200mg tab only for a 200mg dose, and 400mg tab only for a 400mg dose, and 600mg tab only for a 600mg dose). Neonates and infants ≤3months: max 30mg/kg per day in divided doses every 12hrs. >3months: Mild to moderate ENT, skin, or genitourinary: 25mg/kg per day in divided doses every 12hrs or, 20mg/kg per day in divided doses every 8hrs. Lower respiratory or severe ENT, skin, or genitourinary: 45mg/kg per day in divided doses every 12hrs or, 40mg/kg per day in divided doses every 8hrs. Gonorrhea: ≤2yrs: not recommended; >2yrs: 50mg/kg with 25mg/kg probenecid once. >40kg: use other forms. Renal dysfunction (CrCl <30mL/min): <12yrs: not recommended; ≥12yrs: reduce dose, see literature.
Cephalosporin, imipenem, or other allergy: not recommended. Monitor blood, renal, and hepatic function in long-term use. Pregnancy (Cat.B). Nursing mothers.
May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln. Serum levels increased by probenecid.
GI upset, hypersensitivity reactions (eg, urticaria, rash, Stevens-Johnson syndrome, anaphylaxis), hyperactivity, blood dyscrasias.
Formerly known under the brand name Dispermox.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline